Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states-Reference-Cited by-同舟云学术

Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states

Published:2023-09 Issue: Volume:250 Page:110875
ISSN:0376-8716
Container-title:Drug and Alcohol Dependence
language:en
Short-container-title:Drug and Alcohol Dependence

Author:

Hammerslag Lindsey^ORCID,Talbert Jeffery^ORCID,Donohue Julie M.,Sharbaugh Michael,Ahrens Katherine,Allen Lindsay^ORCID,Austin Anna E.,Gordon Adam J.,Jarlenski Marian,Kim Joo Yeon,Mohamoud Shamis^ORCID,Tang Lu^ORCID,Burns Marguerite^ORCID

Funder

Pennsylvania Department of Human Services

National Institute on Drug Abuse

Publisher

Elsevier BV

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Toxicology

Reference34 articles.

1. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update;J. Addict. Med.,2020

2. Trends in use of medication to treat opioid use disorder during the COVID-19 pandemic in 10 state medicaid programs;Austin;JAMA Health Forum,2023

3. Use of telemedicine for buprenorphine inductions in patients with commercial insurance or medicare advantage;Barsky;JAMA Netw. Open,2022

4. Definitive urine drug testing in office-based opioid treatment: a literature review;Barthwell;Crit. Rev. Toxicol.,2018

5. Racial differences in primary care opioid risk reduction strategies;Becker;Ann. Fam. Med.,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary care professionals’ perspectives on tailoring buprenorphine training for rural practice;The Journal of Rural Health;2024-03-14

2. Association of random and observed urine drug screening with long-term retention in opioid treatment programs;Drug and Alcohol Dependence;2024-02